Protons are being used in radiation therapy because of typically better dose conformity and reduced total energy deposited in the patient as compared with photon techniques. Both aspects are related to the finite range of a proton beam. The finite range also allows advanced dose shaping. These benefits can only be fully utilized if the end of range can be predicted accurately in the patient. The prediction of the range in tissue is associated with considerable uncertainties owing to imaging, patient set-up, beam delivery, interfractional changes in patient anatomy and dose calculation. Consequently, a significant range (of the order of several millimetres) is added to the prescribed range in order to ensure tumour coverage. Thus, reducing range uncertainties would allow a reduction of the treatment volume and reduce dose to potential organs at risk.To understand the true uncertainties and to reduce delivery errors, in vivo verification of the delivered dose or range would be highly desirable. The obvious choice is the use of in vivo dosimetry detectors that would allow real-time dose reporting.1 However, this approach is only feasible for very few indications, such as prostate cancer, where detectors could be placed on the rectal balloon used for immobilization. A more promising approach is the use of imaging methods. To use imaging devices in order to monitor treatment delivery is common practice in photon therapy where each beam penetrates the patient so that the exit dose can be measured. Protons on the other hand stop in the patient, and thus imaging can only be based on secondary radiation that is being created by the primary beam. Various methods have been proposed. For instance, MRI can be used to monitor tissue changes owing to radiation, which could potentially allow dosimetric verification.2 The downside of this method is that it cannot be used for online verification because the changes appear days or even months after treatment.The two most promising methods for online verification are based on the fact that protons undergo nuclear interactions in tissue.3 These interactions can lead to photons that are energetic enough to penetrate the patient. For example, nuclei can be left in an excited state, which leads to highenergy (MeV) g-radiation emitted shortly after the interaction of the primary proton with the nucleus. This radiation is thus called prompt g-radiation. This method is very promising for the future but is currently not practical because of the lack of appropriate systems to detect these g-rays with high efficiency and spatial resolution in a clinical setting. Thus, substantial research is still needed before this approach can find its way into clinical practice (see below).The currently more practical approach is the use of positron emission tomography (PET) imaging. The idea to use PET for proton range verification dates back to the 1970s 3,4 but was initially mentioned in pion therapy.5 Nuclear interactions of the proton beam in tissue can result in positron-emitting isotopes.6 ...